These hepatic effects are particularly relevant given the high prevalence of metabolic dysfunction-associated fatty liver disease in the Asian populations studied and position mazdutide as a potential therapeutic for MASH in addition to obesity
Side Effects & Risk Management Every medical treatment has potential side effects, and GLP-1 injections are no exception
Published Phase 2 data (NEJM, 2023) showed retatrutide achieving up to 24.2% mean weight reduction at 48 weeks exceeding outcomes seen with dual GLP-1/GIP agonists
Anthocyanins have profound anti-inflammatory, radical scavenging, and antioxidant properties (Castaneda-Ovando et al
A comprehensive review of conventional and stimuli-responsive delivery systems for bioactive peptides: from food to biomedical applications
The brand structure follows a similar pattern: Victoza and Ozempic are approved for type 2 diabetes, while Saxenda and Wegovy are approved for weight management
